Technical Exchange 2024

For decades, the malaria community waited for a safe and effective malaria vaccine. At this year's Technical Exchange, we discussed how to ensure the real-world effectiveness of these vaccines through high coverage and successful implementation of complementary interventions.

This year's Technical Exchange focused on the new malaria vaccines and ways to scale-up work. For decades, the malaria community waited for a safe and effective malaria vaccine. In October 2021, WHO finally recommended the first malaria vaccine for children (RTS,S/ASO1) and two years later, a second vaccine (R21) was approved. Both malaria vaccines can prevent around 75% of malaria episodes when given seasonally in areas of highly seasonal transmission and in combination with malaria chemoprevention.

While the malaria vaccines represent an important complementary tool to counter the malaria resurgence in moderate-to-high transmission settings, their real-world effectiveness also depends on achieving a high coverage and on the implementation of complementary interventions. Read more.